Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target

Khaled Zeitoun, K M Zeitoun, S E Bulun, Serdar E. Bulun
Fertility and Sterility · 1999 · vol. 72(6) , pp. 961–969 · doi:10.1016/s0015-0282(99)00393-3 · PMID:10593363 · W2170554336
review OA: closed CC0 ⤵ 190 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Aromatase plays a critical role in the development of endometriosis and represents a promising target for future therapeutic interventions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Aromatase Endometriosis Enzyme Inhibitors Aromatase Aromatase Aromatase Inhibitors Endometriosis Endometriosis Endometriosis Endometrium Endometrium Enzyme Inhibitors Epithelial Cells Epithelial Cells Estrogens Estrogens Female Gene Expression Regulation, Enzymologic Gene Expression Regulation, Enzymologic Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:24.024533+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK